The tool overcomes penetration problems by using a human cancer cell line and avoids the interference of different effects by measuring the protein expression of whole cells as an endpoint after exposure to EDCs in comparison to well-known agonists and antagonists of the estrogen receptor. Here, ESR1 is linked to cancer.